Purchase this article with an account.
Abdhish R Bhavsar; ERG/EOG Study in AMD Patients Treated with Ranibizumab (RAPTR). Invest. Ophthalmol. Vis. Sci. 2017;58(8):3212.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The objective of this study is too determine the quantitative changes in the electrophysiologic amplitudes and latencies from baseline to month 12 in ranibizumab-treated eyes with exudative AMD (age related macular degeneration).
This is an open label study assessing ERG (electroretinogram) and EOG (electrooculogram) outcomes in patients with exudative AMD. ERG and EOG testing were conducted at baseline, and at 6 and 12 months after initiating ranibizumab treatment. Ten patients with exudative AMD were enrolled and received monthly intravitrous ranibizumab injections.
No statistically significant differences were identified in ERG or EOG testing including: single photopic flash, maximal photopic response, rod response, 30 Hz flicker, notation of oscillatory potentials, multifocal ERG, EOG testing.
Monthly intravitreous injection of ranibizumab for treatment of exudative AMD did not demonstrate statistically significant ERG or EOG changes over the course of 1 year treatment.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.
This PDF is available to Subscribers Only